Short answer
Abbott Laboratories (ABT) filed its fiscal 2025 10-K annual report with the SEC on Feb 20, 2026. It reported revenue of $44.3B (+5.7% year over year) and net income of $6.5B.
- Top risk flagged: IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
FY2025 key financial metrics · XBRL
- Revenue
- $44.3B
- +5.7% YoY
- Net income
- $6.5B
- −51.3% YoY
- Operating margin
- 18.2%
- +1.9 pp YoY
- EPS (diluted)
- $3.72
- −51.3% YoY
- ROE
- 12.5%
- −15.6 pp YoY
- Operating cash flow
- $9.6B
- +11.8% YoY
Source: XBRL data from the Abbott Laboratories (ABT) FY2025 10-K on SEC EDGAR. USD.
Abbott Laboratories FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
- Strategic shift: Amended and restated By-Laws effective December 12, 2025, indicating governance updates
- Quantitative metric: Allowances for doubtful accounts and product returns increased to $490M in 2025 from $439M in 2024
- Most noteworthy fact: Inclusion of significant merger-related documents and ongoing update of compensation and governance policies in 2026 Proxy Statement
Management Discussion & Analysis
- Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
- Best segment: Medical Devices sales up 12.6% (to approx. $19.9B); worst: Diagnostics sales down 4.3% with margin decline to 19.5% from 24.4%
- Cash and short-term investments $8.9B; long-term debt $12.9B; dividends $4.1B, increased 7.1% to $2.40/share in 2025
- 2026 outlook: focus on growth in diagnostics (Alinity platform), medical devices, nutrition product innovation and emerging market pharmaceutical expansion
Risk Factors
- IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
- Supply chain tariffs and foreign exchange fluctuations increased costs, partially offsetting margin improvement which led to only a 52.6% gross margin in 2025
- Competitive pressure from biosimilars and off-patent medicines expansion in emerging markets challenges Established Pharmaceuticals segment growth
- Debt maturity exposure with $3.0B of $12.9B total debt due in 2026, plus $20B unsecured bridge loan commitment related to Exact Sciences acquisition
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.